

WHO Classification	Disorders	Etiology		Work-up	Management
		Normosomic	Kallmann		
Group I: Hypogonadotropic Hypogonadal Anovulation	Idiopathic hypogonadotropic hypogonadism (IHH)	Mutations of GNRHR, ANOS1, FGFR3/FGFR1, TACR3, CCDC141, NELF ²	Interrupted GnRH neuron migration from nasal placode; FGFR1, ANOS1 (KAL1), FGFR3, FGFR1, IL17RD, DUSP6, SPRY4, FLRT3, KLB, PROK2, PROKR2, HES6ST1, CHD7, WDR11, SEMA3A, SEMA3E, IGSF10, SMCHD1, CCDC141, FEZF1, HESX1	- Brain MRI - FSH, LH	- Transdermal estradiol patch; gradually increase dose - Conjugated equine estrogen with Cyclic medroxyprogesterone 10mg 12-14 days/month - combined oral contraceptive pill - Fertility treatment: recombinant FSH, human menopausal gonadotropin
	Septo-Opto Dysplasia	- Vascular insult in 6th-7th week of embryogenesis - HESX1 mutation - Associated risk factors: - 1 st trimester bleeding - Illicit drug use - Primiparity		- Brain MRI - FSH, LH	- Neurodevelopmental monitoring - Combined oral contraceptive pill - Estradiol patch or oral conjugated equine estradiol with cyclic medroxyprogesterone
	Panhypopituitarism	- Pituitary tumors - Traumatic brain injury - Inflammatory changes ((Mycobacterium Tuberculosis, histoplasmosis, syphilis, viruses, protozoa, lymphocytic hypophysitis) - Infiltrative disease (Histiocytosis, hemochromatosis, sarcoidosis) - Pituitary apoplexy, Sheehan's syndrome - Congenital (genetic mutation of HESX1, PROP1, and Pit-1) - Empty Sella Syndrome		- Brain MRI - FSH, LH - TSH, ACTH	- Combined oral contraceptive pill - Estradiol patch or oral conjugated equine estradiol with cyclic medroxyprogesterone - Correct other endocrinopathies - Fertility treatment: recombinant FSH, human or menopausal gonadotropin
	Craniopharyngioma	- Embryonic theory: arises from remnants of Rathke's pouch - Metaplastic theory: metaplasia of squamous epithelial cell rests from stomodaeum - Mutations in CTNNB1 that encodes β -catenin		- Brain MRI - FSH, LH	- Radiotherapy or subtotal resection - Fertility treatment: recombinant FSH, human menopausal gonadotropin
	Langerhans Histiocytosis X	- Somatic mutations gain of function in BRAF gene in 50% of cases		- Brain MRI - FSH, LH - Prolactin, TSH, ACTH - Basic metabolic profile	- Radiotherapy - Correct endocrinopathy - Fertility treatment: human menopausal gonadotropin (hMG)
Group II: Irregularities in HPO Axis	Polycystic Ovarian Syndrome	- Multifactorial - Candidate genes mutated: GLUT4, miR-93		- Total testosterone - 17-hydroxyprogesterone - Dehydroepiandrosterone-dione sulfate - 2-hour glucose tolerance test - Lipid panel - Transvaginal ultrasonography	- Combined oral contraceptive pill - Fertility treatment: First line- letrozole Second line- clomiphene citrate
	Hyperprolactinemia	- Prolactinoma - Primary hypothyroidism - Autoimmune disorders - Chronic renal failure - Psychotropic medications		- Prolactin - TSH - MRI of the pituitary fossa	- Cabergoline - Bromocriptine - Surgical decompression if medical management fails
	Thyroid dysfunction	Hyperthyroidism - Hashimoto's thyroiditis - Lymphocytic thyroiditis - Radiation therapy - Surgery - De Quervain - Infiltrative sarcoidosis - Hemochromatosis - Drugs (Lithium, Amiodarone)	Hypothyroidism - Graves disease - Iatrogenic (drug induced, TKI, INF α) - Inadequate iodine - Struma ovarii - Infection	- TSH - Total and free T4 - Consider total and free T3	- Levothyroxine if hypothyroid - Methimazole or propylthiouracil if hyperthyroid
	Endometriosis	- Multifactorial - miR-135a overexpression - Copy number variants: 1p36, 7p22.1 and 22q12		- Diagnostic laparoscopy	- Surgical ablation of lesions - Ovulation induction agents
Group III: Hypergonadotropic Hypogonadal Anovulation	Primary Ovarian Insufficiency	- Genetic (Turner's, Fragile X) - Acquired (autoimmune, environmental) - Iatrogenic (chemotherapy agents, drugs, brain radiation)		- AMH - Karyotype - FMR1 pre-mutation	- Combined oral contraceptive pill - Estradiol patch or oral conjugated equine estradiol with cyclic medroxyprogesterone Fertility treatment: - Oocyte or ovarian tissue* cryopreservation - IVF with donor oocytes - Stem cell therapy* - AUGMENT* *still considered experimental

Table S1. Summary of group I-III ovulation disorders including etiology, evaluation and management.